Status:
COMPLETED
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare the efficacy of metformin and repaglinide used alone or combined administered as initial treatment in subjects with type 2 diabet...
Eligibility Criteria
Inclusion
- Subjects with type 2 diabetes
- Treated by diet for at least 3 months
- Never treated with hypoglycaemic drugs
- HbA1c (glycaemic haemoglobin A1c) on inclusion time superior to 6.5%
Exclusion
- Very symptomatic diabetes
- Advanced vascular complications
- Manifest renal failure
- Manifest hepatic disease
- Pregnancy, breast feeding or intention to become pregnant or if it is considered that the patient is not using adequate contraceptive measures. Adequate contraceptive measures are considered to be an intrauterine device, oral contraceptives and barrier methods
Key Trial Info
Start Date :
March 6 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2004
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT01465152
Start Date
March 6 2002
End Date
October 21 2004
Last Update
February 20 2017
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Barcelona, Spain, 08020
2
Novo Nordisk Investigational Site
Benamargosa, Spain, 29718
3
Novo Nordisk Investigational Site
Burlata, Spain, 31600
4
Novo Nordisk Investigational Site
Camas, Spain, 41900